Many risk factors of lung cancer are known, and its pre-malignant state continues to emerge through insights in genetic markers, disease heterogeneity and pathogenesis.1 Still, lung cancer is the leading cause of cancer death worldwide, claiming the lives of about 1.8 million people per year.2
The incidence and prevalence of type 1 diabetes (T1D) are increasing around the world.i Globally, more than one million children under the age of 20 have T1D, with over 130,000 new diagnoses each year.ii Diabetic ketoacidosis (DKA), a hallmark of T1D, accounts for 14 percent of all hospital admissions of patients with diabetes and 16 percent of all diabetes-related fatalities, and among patients with T1D, DKA is much more common in young children and adolescents than it is in adults.
As scientists in the field of infectious diseases, it is our life’s work to research and develop solutions to some of the world’s most challenging and dangerous health concerns. While we have made tremendous strides over the last several decades, antimicrobial resistance (AMR), recognized by the World Health Organization as one of the top 10 threats to global health,1,2 could endanger much of the progress we have made.
In the more than 40 years since the global HIV epidemic began, the world has made significant progress against the virus. Major strides have been taken in developing treatment and prevention options and providing access to these life-changing medicines and health technologies across the globe.
Two billion.
This World Neglected Tropical Diseases (NTD) Day, Johnson & Johnson is pleased to announce that this is the number of doses of mebendazole, our medicine to treat intestinal worms, that we have donated for people in need in more than 50 resource-limited countries around the world. It’s the latest achievement in a donation program we launched in 2006 that is helping children, who are particularly vulnerable to intestinal worms, grow, learn, and thrive.
But it’s more than just a milestone.
In honor of Black History Month, Janssen is spotlighting its commitment to increase diversity among its clinical trial participants, and to expand community engagement to build awareness of, and trust in, clinical research within Black communities and other communities of color.
When most people hear the term 'data science,' they probably think of people sitting at their laptops feverishly crunching numbers using fancy formulas with massive spreadsheets and data visualizations. And, in fairness, that is part of the average day in the life of a data scientist.
Imagine a world where a recording of a person’s voice could help healthcare professionals more quickly detect a neurological condition.
Thanks to efforts across the Clinical Innovation, Data Science and Neuroscience teams at Janssen, along with other internal and external strategic partners, this reality may now be close at hand. Recent developments in speech biomarker technology may be able to help predict results of current diagnostic procedures for Alzheimer’s disease (AD). This discovery has the potential to improve clinical trials and patient outcomes.
For decades, vaccines have had an unparalleled impact on global public health and remain one of the most effective methods of preventing infectious diseases worldwide.
Clinical trials are a hugely complex enterprise that depend on the expertise, organization and dedication of many scientists, engineers, clinicians, project managers and their teams, strong collaboration with doctors, nurses, hospitals and their clinical teams and collaborations with governments and health care regulators. Most importantly, clinical trials rely on the participation of volunteers, patients, caregivers and we hope these trials will lead to the advancement of new medicines. What we do is complex but is also an amazing opportunity to make a difference in the
